Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Sinusoidal obstruction syndrome following CD33-targeted therapy in acute myeloid leukemia.

Literature DB >> 28153826

Sinusoidal obstruction syndrome following CD33-targeted therapy in acute myeloid leukemia.

Colin D Godwin¹, George B McDonald^2,3, Roland B Walter^2,4,5.

Abstract

Entities: Disease Gene

Mesh：

Substances：

Year: 2017 PMID： 28153826 PMCID： PMC5399486 DOI： 10.1182/blood-2017-01-762419

Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113

× No keyword cloud information.

24 in total

1. The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging.

Authors: Fabricio Montalvao; Zacarias Garcia; Susanna Celli; Béatrice Breart; Jacques Deguine; Nico Van Rooijen; Philippe Bousso
Journal: J Clin Invest Date: 2013-11-01 Impact factor: 14.808

2. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.

Authors: P F Bross; J Beitz; G Chen; X H Chen; E Duffy; L Kieffer; S Roy; R Sridhara; A Rahman; G Williams; R Pazdur
Journal: Clin Cancer Res Date: 2001-06 Impact factor: 12.531

Review 3. Sinusoidal obstruction syndrome (hepatic veno-occlusive disease).

Authors: Cathy Q Fan; James M Crawford
Journal: J Clin Exp Hepatol Date: 2014-10-30

4. Experimentally induced liver metastases from colorectal cancer can be prevented by mononuclear phagocyte-mediated monoclonal antibody therapy.

Authors: Gerben J van der Bij; Marijn Bögels; Marielle A Otten; Steven J Oosterling; Peter J Kuppen; Sybren Meijer; Robert H J Beelen; Marjolein van Egmond
Journal: J Hepatol Date: 2010-06-17 Impact factor: 25.083

Review 5. Hepatotoxicity of Pyrrolizidine Alkaloids.

Authors: Manuela G Neuman; Lawrence Cohen; Mihai Opris; Radu M Nanau; Jeong Hyunjin
Journal: J Pharm Pharm Sci Date: 2015 Impact factor: 2.327

6. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project.

Authors: June M McKoy; Cara Angelotta; Charles L Bennett; Martin S Tallman; Martha Wadleigh; Andrew M Evens; Timothy M Kuzel; Steve M Trifilio; Dennis W Raisch; Jonathan Kell; Daniel J DeAngelo; Francis J Giles
Journal: Leuk Res Date: 2006-09-07 Impact factor: 3.156

7. Bone marrow progenitor cells repair rat hepatic sinusoidal endothelial cells after liver injury.

Authors: Rula Harb; Guanhua Xie; Carolyn Lutzko; Yumei Guo; Xiangdong Wang; Colin K Hill; Gary C Kanel; Laurie D DeLeve
Journal: Gastroenterology Date: 2009-05-15 Impact factor: 22.682

8. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.

Authors: May S Kung Sutherland; Roland B Walter; Scott C Jeffrey; Patrick J Burke; Changpu Yu; Heather Kostner; Ivan Stone; Maureen C Ryan; Django Sussman; Robert P Lyon; Weiping Zeng; Kimberly H Harrington; Kerry Klussman; Lori Westendorf; David Meyer; Irwin D Bernstein; Peter D Senter; Dennis R Benjamin; Jonathan G Drachman; Julie A McEarchern
Journal: Blood Date: 2013-06-14 Impact factor: 22.113

9. Incidence of sinusoidal obstruction syndrome following Mylotarg (gemtuzumab ozogamicin): a prospective observational study of 482 patients in routine clinical practice.

Authors: Martin S Tallman; George B McDonald; Laurie D DeLeve; Maria R Baer; Michael N Cook; G Jay Graepel; Carl Kollmer
Journal: Int J Hematol Date: 2013-03-05 Impact factor: 2.490

10. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias.

Authors: J M Burke; P C Caron; E B Papadopoulos; C R Divgi; G Sgouros; K S Panageas; R D Finn; S M Larson; R J O'Reilly; D A Scheinberg; J G Jurcic
Journal: Bone Marrow Transplant Date: 2003-09 Impact factor: 5.483

17 in total

Review 1. Immune-Based Therapies in Acute Leukemia.

Authors: Matthew T Witkowski; Audrey Lasry; William L Carroll; Iannis Aifantis
Journal: Trends Cancer Date: 2019-08-29

2. Liver Complications Following Treatment of Hematologic Malignancy With Anti-CD22-Calicheamicin (Inotuzumab Ozogamicin).

Authors: George B McDonald; James W Freston; James L Boyer; Laurie D DeLeve
Journal: Hepatology Date: 2019-01-18 Impact factor: 17.425

Review 3. Gemtuzumab ozogamicin in acute myeloid leukemia.

Authors: C D Godwin; R P Gale; R B Walter
Journal: Leukemia Date: 2017-06-13 Impact factor: 11.528

Review 4. Oncology stewardship in acute myeloid leukemia.

Authors: Madeleine A Ochs; Bernard L Marini; Anthony J Perissinotti; Charles E Foucar; Kristen Pettit; Patrick Burke; Dale L Bixby; Lydia L Benitez
Journal: Ann Hematol Date: 2022-05-26 Impact factor: 4.030

5. Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms.

Authors: Colin D Godwin; Eduardo Rodríguez-Arbolí; Megan Othus; Anna B Halpern; Jacob S Appelbaum; Mary-Elizabeth M Percival; Paul C Hendrie; Vivian G Oehler; Siobán B Keel; Janis L Abkowitz; Jason P Cooper; Ryan D Cassaday; Elihu H Estey; Roland B Walter
Journal: Cancers (Basel) Date: 2022-06-14 Impact factor: 6.575

6. ImmunoPET, [⁶⁴Cu]Cu-DOTA-Anti-CD33 PET-CT, Imaging of an AML Xenograft Model.

Authors: Sargur Madabushi Srideshikan; Jamison Brooks; Darren Zuro; Bijender Kumar; James Sanchez; Liliana Echavarria Parra; Marvin Orellana; Paresh Vishwasrao; Indu Nair; Junie Chea; Kofi Poku; Nicole Bowles; Aaron Miller; Todd Ebner; Justin Molnar; Joseph Rosenthal; Daniel A Vallera; Jeffrey Y C Wong; Anthony S Stein; David Colcher; John E Shively; Paul J Yazaki; Susanta K Hui
Journal: Clin Cancer Res Date: 2019-09-23 Impact factor: 12.531